Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

23.47 +0.34 (+1.47%)
Streaming Delayed Price Updated: 12:16 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary
Via Stocktwits
Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug
Goldman Sachs cited Apellis’ 6% quarterly injection growth for Syfovre and potential market upside from Empaveli’s newly approved indications in C3G and IC-MPGN, despite recent revenue headwinds from... 
Via Stocktwits
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Apellis Pharmaceuticals's Earnings Outlook
 
Via Benzinga
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss
Apellis Pharmaceuticals (APLS) reported mixed Q2 2025 results, missing revenue estimates ($178.49M vs. $192.29M) but beating EPS (-$0.33 vs. -$0.49). Shares rose 4.58% pre-market as FDA approval for... 
Via Chartmill
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio
FDA approves Apellis' Empaveli for rare kidney diseases, with trial data showing strong efficacy in reducing proteinuria and clearing C3 deposits. 
Via Benzinga
Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals
The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial. 
Via Stocktwits
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
 
Via Benzinga
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals
 
Via Benzinga
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.; Sobi
Via GlobeNewswire
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts
 
Via Benzinga
Why Apellis Pharmaceuticals Wilted on Wednesday
Via The Motley Fool
Topics Earnings
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals
 
Via Benzinga
Apellis Announces Craig Wheeler to Join the Board of Directors
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
Via Benzinga
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre
JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.